Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Leukemia & Lymphoma

Font Size

New Cancer Treatment Zaps Lymphoma

WebMD Health News
Reviewed by Gary D. Vogin, MD


May 15, 2002 -- A new generation of anticancer treatments can prolong the lives of patients with hard-to-treat cases of non-Hodgkin's lymphoma who have exhausted all other options. New research shows the first of a class of drugs that uses radioimmunotherapy to hone in on and kill cancers is also effective at zapping non-Hodgkin's lymphoma B cells.

The study appears in today's issue of the Journal of Clinical Oncology.

Radioimmunotherapy uses laboratory-created antibodies, similar to those produced by the body in response to cancers, to target radiation treatment directly at the site of the cancer. The mixture of antibodies and radiation is delivered intravenously and travels through the blood to the cancer cells.

Researchers at the Mayo Clinic studied the ability of the first radioimmunotherapy drug designed specifically to treat low-grade B cell non-Hodgkin's lymphoma, Zevalin. About 56,000 Americans are diagnosed each year with this common, but usually fatal, type of cancer of the lymph glands.

The researchers found that 80% of patients who received Zevalin had a positive response to the drug and their tumor shrank, compared with only 56% who had a similar response to another drug used to treat the cancer, Rituxan. Also, 30% of the patients using Zevalin had a complete remission of their disease with no trace of the cancer present, compared with only 16% of those taking Rituxan.

Since the drug targets only the cancer cells it's designed to destroy, researchers say the treatment is more effective than traditional approaches and has fewer side effects.

"Unlike chemotherapy which goes through the whole body, Zevalin carries the radiation payload directly to the tumor," says study author Thomas Witzig, MD, a hematologist at the Mayo Clinic, in a news release. "The drug radiates only about a 5 mm area around the tumor."

"One treatment is required on an outpatient basis, compared to a series of treatments with chemotherapy that can last four to six months and sometimes include hospitalization because of serious side effects," says Witzig. "There's no hair loss or prolonged fatigue, nausea, or vomiting. The most significant side effect is a temporary decrease in the blood count."

Based on the results of this phase III clinical trial and others, the FDA recently approved Zevalin for treatment of patients with relapsed B cell non-Hodgkin's lymphoma.

Today on WebMD

stem cells
What are they and why do we need them?
Lung cancer xray
See it in pictures, plus read the facts.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Do you know the symptoms?
Vitamin D
New Treatments For Non-Hodgkins Lymphoma
Lifestyle Tips for Depression Slideshow
Pets Improve Your Health